XRTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

FY2025Q1

-0.290

-38.3%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for XORTX Therapeutics Inc. (XRTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -29.82%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-29.82%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for XORTX Therapeutics Inc (XRTX.O) is -1.22, compared to its 5-year average forward P/E of -2.13. For a more detailed relative valuation and DCF analysis to assess XORTX Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.13

Current PE

-1.22

Overvalued PE

-0.22

Undervalued PE

-4.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.26

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.26

Undervalued EV/EBITDA

-1.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.45

Current PS

0.00

Overvalued PS

1.52

Undervalued PS

-0.61

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XRTX News & Events

Events Timeline

No data

News

9.5

11-03Benzinga

Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading

7.0

10-21SeekingAlpha

XORTX Therapeutics Secures 180-Day Extension from Nasdaq to Meet $1.00 Bid Price Requirement

7.0

10-20Newsfilter

XORTX Receives Nasdaq Notification Concerning Minimum Bid Price Shortfall

People Also Watch

Frequently Asked Questions

What is XORTX Therapeutics Inc (XRTX) stock price today?

The current price of XRTX is 0.6 USD — it has decreased -1.64 % in the last trading day.

What is XORTX Therapeutics Inc (XRTX)'s business?

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

What is the price predicton of XRTX Stock?

Wall Street analysts forecast XRTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is XORTX Therapeutics Inc (XRTX)'s revenue for the last quarter?

XORTX Therapeutics Inc revenue for the last quarter amounts to -716.20K USD, decreased -18.13 % YoY.

What is XORTX Therapeutics Inc (XRTX)'s earnings per share (EPS) for the last quarter?

XORTX Therapeutics Inc. EPS for the last quarter amounts to -635103.00 USD, decreased -18.05 % YoY.

What changes have occurred in the market's expectations for XORTX Therapeutics Inc (XRTX)'s fundamentals?

How many employees does XORTX Therapeutics Inc (XRTX). have?

XORTX Therapeutics Inc (XRTX) has 2 emplpoyees as of December 16 2025.

What is XORTX Therapeutics Inc (XRTX) market cap?

Today XRTX has the market capitalization of 4.18M USD.